

****Updated March 2016****

MarketVIEW: RSV vaccines (CAT: VAMV023)

Product Name	:	MarketVIEW: Respiratory Syncytial Virus vaccines
Description	:	Global vaccine commercial opportunity assessment
Contents	:	Executive presentation (.pdf) + forecast model (.xls)
Therapeutic Area	:	Novel pediatric and elderly vaccines
Publication date	:	March 2016
Catalogue No	:	VAMV023

Background

Respiratory Syncytial Virus (RSV) is a leading cause of acute infant/childhood (< 5yrs) lower respiratory tract infections (ALRIs) and hospitalization. In particular, elderly adults and/or those with underlying co-morbidities such as chronic obstructive pulmonary disease (COPD) or suffering with malignancies are also at increased risk of RSV infection related complications. On a global basis, RSV is estimated to be responsible for 30 million episodes and 53,000 to 199,000 deaths per year, mostly children. 99% of deaths occur in developing countries.

An RSV prophylactic vaccine would ideally to reduce the incidence of severe RSV lower respiratory tract infections in “at risk” groups. Currently a number of approaches are being pursued including live-attenuated viruses and/or recombinant proteins, the most advanced of which is from US biotech Novavax (RSV-F) who have recently entered Phase III trials with a VLP recombinant fusion protein. An adult filing is expected in 1H 2007.

This **MarketVIEW** product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of new RSV vaccines across global markets¹ to 2035. The model contains value (\$ m) and volume (mio doses) predictions for infants (<1yrs) and various adult target groups (maternal, elderly and “at risk”). Differing RSV vaccine profiles (infant + maternal + elderly) and related issues such as differential pricing are also discussed along with an up-to-date review of epidemiology and the competitive environment, R&D pipeline.

¹ High income, PAHO (Latin America), Asia, Middle-East, Africa (Non-GAVI) and GAVI

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to RSV epidemiology/vaccines. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the field of respiratory pathogens has also been utilised.

PRODUCT CONTENTS:

Published March 2016 (CAT No: VAMV023)

****This product is composed of a model (.xls)² and summary presentation (.pdf)

Executive summary
Authors note
Contents
Executive summary
RSV vaccines: Commercial model - key outputs
Predicted global sales (\$m) by target segment, 2015-2035
Predicted infant and maternal immunization sales (\$m), 2015-2035
Predicted infant immunization sales (\$m) by country/region, 2030
Predicted maternal immunization sales (\$m) by country/region, 2030
Predicted elderly and at-risk immunizations sales (\$m), 2015-2035
Predicted elderly immunization sales (\$m), by country/region, 2030
Predicted "at-risk" immunization sales (\$m), by country/region, 2030
Predicted global volume per segment (doses) to 2035
RSV vaccines: Commercial model - key assumptions
The role of RSV vaccines
RSV vaccine target populations: overview
RSV vaccine: infant target product profile (TPP)
RSV vaccine: maternal immunization target product profile (TPP)
RSV vaccine: elderly/at-risk target product profile (TPP)
Markets/regions included in model
RSV vaccine predicted uptake per country/region
Forecast comparisons: March 2016 vs. April 2014*
Pricing: infant and maternal immunization
Pricing: elderly and at-risk immunization
Pricing: elderly and at-risk immunization (cont..)
RSV vaccines: R&D pipeline
Competitor landscape: overview
Novavax: elderly immunization
Novavax: elderly immunization - Phase III
Novavax: elderly immunization - trial review
Novavax: maternal immunization
Novavax: maternal immunization - Phase II results
Novavax: maternal immunization - US seasons

² Model contents are available upon request only

Continued.....

Novavax: maternal immunization - Phase III
Novavax: maternal immunization - trial review
Novavax: infant immunization
GSK: maternal and infant immunization
Other companies with clinical stage RSV vaccines
RSV - review of latest epidemiology
Epidemiology: overview (*3 slides*)
RSV disease burden: infants
RSV disease burden: US infants
RSV disease burden: infants – hospitalizations
RSV disease burden: infants – bronchiolitis
RSV disease burden: infants – lower income countries
RSV disease burden: infants – India
RSV disease burden: infants – vaccine strategy
RSV disease burden: elderly (*8 slides*)
RSV disease burden: elderly – Cardiopulmonary disease
Back-up material
Methodology – populations
Methodology – vaccine uptake (*14 slides*)
Bibliography
About **VacZine Analytics**
Disclaimer

PAGES: 82 MS slides available in .pdf form

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- USD \$9995.00/ GBP £7000.00# (Region license)*

*A region is North America, Europe or ROW

For orders in the UK, VAT at 20% will be added to final invoice total

- *indicative prevailing rate will be applied on date of transaction*

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com

This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and the “**spiral logo**” are UK Registered Trademarks, 2009

BIBLIOGRAPHY

1. Régnier SA. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine. *Vaccine*. 2013 Sep 13;31(40):4347-54.
2. Rotavirus vaccine to be introduced for babies. Available at: <http://www.nhs.uk/news/2012/11November/Pages/New-vaccine-to-prevent-rotavirus-diarrhoea-in-babies.aspx>
3. PAHO. Revolving Fund Prices. Available at: <http://www.paho.org/>
4. CDC Vaccine Price List Prices last reviewed/updated: March 2016. Available at: <http://www.cdc.gov/vaccines/programs/vfc/cdc-vac-price-list.htm>
5. Meijboom MJ et al. RSV vaccine in development: assessing the potential cost-effectiveness in the Dutch elderly population. *Vaccine*. 2013 Dec 16;31(52):6254-60.
6. Novavax. JP Morgan Annual Healthcare Conference. January 2016. Available at: Novavax.com. Accessed: February 2016
7. RSV Vaccine Snapshot. Available at: <http://sites.path.org/vaccinedevelopment/respiratory-syncytial-virus-rsv/>
8. Novavax Announces Positive Top-Line Data from Phase 2 RSV F-Protein Vaccine Clinical Trial in Older Adults. August 2015. Available at: <http://ir.novavax.com/phoenix.zhtml?c=71178&p=irol-newsArticle&ID=2078538>
9. One Year Follow-Up From RSV F-Protein Vaccine Candidate Phase 1 Elderly Trial Demonstrates Sustained Levels of Immune Response. May 2014. Available at: <http://ir.novavax.com/phoenix.zhtml?c=71178&p=irol-newsArticle&ID=1929787>
10. Novavax 10K. For the fiscal year ended December 31, 2014. Available at: <http://ir.novavax.com/>
11. Novavax Announces Positive Top-Line Data from Phase 2 Clinical Trial of RSV F Vaccine to Protect Infants via Maternal Immunization. September 2015. Available at: <http://ir.novavax.com/phoenix.zhtml?c=71178&p=irol-newsArticle&ID=2091286>
12. CDC. Respiratory Syncytial Virus Infection (RSV). Available at: <http://www.cdc.gov/rsv/research/us-surveillance.html>
13. Novavax Initiates Global Pivotal Phase 3 Trial of the RSV F Vaccine to Protect Infants via Maternal Immunization. December 2015. Available at: <http://ir.novavax.com/phoenix.zhtml?c=71178&p=irol-newsArticle&ID=2120087>
14. Novavax Announces Positive Top-Line Data From RSV F Vaccine Phase 1 Clinical Trial in Pediatrics. September 2015. Available at: <http://ir.novavax.com/phoenix.zhtml?c=71178&p=irol-newsArticle&ID=2091524>
15. Dieussaert I. GSK's RSV vaccine product development overview. March 2015. Available at: http://www.who.int/immunization/research/meetings_workshops/rsv_vaccine_development/en/index1.html
16. WHO. Status of Vaccine Research and Development of Vaccines for RSV. June 2014. Available at: http://www.who.int/immunization/research/meetings_workshops/WHO_PDVCAC_RSV.pdf.
17. WHO Informal Consultation on Surveillance of RSV on the Global Influenza Surveillance and Response System (GISRS) Platform 25–27 March 2015, Geneva, Switzerland. http://www.who.int/influenza/resources/publications/report_rsv_meeting/en/
18. Branche AR, Falsey AR. Respiratory syncytial virus infection in older adults: an under-recognized problem. *Drugs Aging*. 2015 Apr;32(4):261-9.
19. Public Health England. Respiratory pathogen circulation, England and Wales, 2004 to 2015. Available at: <https://www.gov.uk/government/publications/respiratory-virus-circulation-england-and-wales>
20. WHO. Hubs to spread technology and save lives. Available at: <http://www.who.int/bulletin/volumes/93/5/15-020515/en/>
21. Nair H et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children. *Lancet*. 2010 May 1;375(9725):1545-55.
22. HCUPnet. Agency for Healthcare Research and Quality. Available at: <http://hcupnet.ahrq.gov/>.
23. Hall CB. et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. *Pediatrics*. 2013 Aug;132(2):e341-8.
24. Murray J. et al. Risk Factors for Hospital Admission with RSV Bronchiolitis in England: A Population-Based Birth Cohort Study. *PLoS One*. 2014 Feb 26;9(2):e89186.
25. Broor S et al. Rates of respiratory virus-associated hospitalization in children aged <5 years in rural northern India. *J Infect*. 2014 Mar;68(3):281-9.
26. Saha S et al. Evaluation of case definitions for estimation of respiratory syncytial virus associated hospitalizations among children in a rural community of northern India. *J Glob Health*. 2015 Dec;5(2):010419.
27. Falsey AR et al. Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illness. *J Infect Dis*. 2014 Jun 15;209(12):1873-81
28. Falsey AR et al. Respiratory syncytial virus infection in elderly and high-risk adults. *N Engl J Med*. 2005 Apr 28;352(17):1749-59.
29. Fleming DM et al. Modelling estimates of the burden of Respiratory Syncytial virus infection in adults and the elderly in the United Kingdom. *BMC Infect Dis*. 2015 Oct 23;15:443.
30. American Lung Association. Available at: <http://www.lung.org/lung-health-and-diseases/lung-disease-lookup/copd/learn-about-copd/how-serious-is-copd.html>
31. Canadian Health Measures Survey: Household and physical measures data, 2012 to 2013. Available at: <http://www.statcan.gc.ca/daily-quotidien/141029/dq141029c-eng.htm>

32. COPD — chronic obstructive pulmonary disease. Available at: <http://www.aihw.gov.au/copd/>
33. European Core Health Indicators. Available at: http://ec.europa.eu/health/major_chronic_diseases/indicators/index_en.htm#fragment0
34. Kein Zusatznutzen belegt für Umeclidinium/Vilanterol bei COPD. Available at: <http://www.idw-online.de>.
35. Gini R et al. Chronic disease prevalence from Italian administrative databases in the VALORE project: a validation through comparison of population estimates with general practice databases and national survey. *BMC Public Health*. 2013 Jan 9;13:15.
36. England. Chronic disease prevalence by age, sex and region in 2008. Available at: <http://www.erpho.org.uk/viewResource.aspx?id=20574>
37. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. *Circulation*. 2016 Jan 26;133(4):447-54
38. Sahle BW et al. Prevalence of heart failure in Australia: a systematic review. *BMC Cardiovasc Disord*. 2016 Feb 6;16(1):32.
39. Ohlmeier C et al. Incidence, prevalence and 1-year all-cause mortality of heart failure in Germany: a study based on electronic healthcare data of more than six million persons. *Clin Res Cardiol*. 2015 Aug;104(8):688-96.
40. Wong CY et al. Trends in comorbidity, disability, and polypharmacy in heart failure. *Am J Med*. 2011 Feb;124(2):136-43.
41. Mascarenhas J et al. Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications. *Am Heart J*. 2008 Mar;155(3):521-5.
42. WHO/UNICEF. Immunization Coverage. Available at: http://www.who.int/immunization/monitoring_surveillance/data/en/
43. PAHO. Influenza vaccine coverage data. Available at: http://www.paho.org/hq/index.php?option=com_content&view=category&layout=blog&id=4048&Itemid=4210
44. European Centre for Disease Prevention and Control. Seasonal influenza vaccination in Europe. Stockholm: ECDC; 2015. Available at: <http://ecdc.europa.eu/en/publications/Publications/Seasonal-influenza-vaccination-Europe-2012-13.pdf>.
45. Flu Vaccination Coverage, United States, 2014-15 Influenza Season. Available at: <http://www.cdc.gov/flu/fluview/cov-1415estimates.htm>
46. Garrastazu R et al. Prevalence of Influenza Vaccination in Chronic Obstructive Pulmonary Disease Patients and Impact on the Risk of Severe Exacerbations. *Arch Bronconeumol*. 2015 Oct 29. pii: S0300-2896(15)00354-3.
47. Chiatti C et al. Determinants of influenza vaccination among the adult and older Italian population with chronic obstructive pulmonary disease: a secondary analysis of the multipurpose ISTAT survey on health and health care use. *Hum Vaccin*. 2011 Oct;7(10):1021-5.
48. Loerbroks A et al. Influenza vaccination coverage among high-risk groups in 11 European countries. *Eur J Public Health*. 2012 Aug;22(4):562-8.
49. Annunziata K et al. Vaccination rates among the general adult population and high-risk groups in the United States. *PLoS One*. 2012;7(11):e50553.
50. MMWR. Influenza Vaccination Coverage Among Pregnant Women — United States, 2014–15 Influenza Season. September 18, 2015 / 64(36):1000-1005. Available at: <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6436a2.htm>
51. Public Health England. Influenza immunisation programme for England. Available at https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/429612/Seasonal_Flu_GP_Patient_Groups_Annual_Report_2014_15.pdf
52. Koul PA et al. Poor uptake of influenza vaccination in pregnancy in northern India. *Int J Gynaecol Obstet*. 2014 Dec;127(3):234-7.
53. WHO. Maternal immunization against tetanus. Available at: http://www.who.int/reproductivehealth/publications/maternal_perinatal_health/immunization_tetanus.pdf.
54. Kharbanda EO et al. Maternal Tdap vaccination: Coverage and acute safety outcomes in the vaccine safety datalink, 2007-2013. *Vaccine*. 2016 Feb 10;34(7):968-73
55. Bödeker B Cross-sectional study on factors associated with influenza vaccine uptake and pertussis vaccination status among pregnant women in Germany. *Vaccine*. 2014 Jul 16;32(33):4131-9.
56. Legge A et al. Rates and determinants of seasonal influenza vaccination in pregnancy and association with neonatal outcomes. *CMAJ*. 2014 Mar 4;186(4):E157-64.

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009